Corrigendum to ‘Validation of high-sensitivity performance for a United States Food and Drug Administration cleared cardiac troponin I assay’ [Clin. Biochem. 56 (2018) 4–10] (S0009912018302972) (10.1016/j.clinbiochem.2018.05.004));Validation of high-sensitivity performance for a United States Food and Drug Administration cleared cardiac troponin I assay

Clinical Biochemistry

Volumn 56, Issue , 2018, Pages 4-10

  Christenson, Robert H ^a   Mullins, Kristin ^a   Duh, Show Hong ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

99th percentile; Cardiac troponin I; Clinical decision value; High sensitivity; Limit of detection; Sex specific

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; HEMOGLOBIN A1C; TROPONIN I; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; ASSAY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; LIMIT OF DETECTION; MALE; NONPARAMETRIC TEST; PRIORITY JOURNAL; QUESTIONNAIRE; SENSITIVITY ANALYSIS; UNITED STATES; VALIDATION STUDY; VERY ELDERLY; ADOLESCENT; BLOOD; COHORT ANALYSIS; DIAGNOSTIC KIT; DIAGNOSTIC TEST APPROVAL; HEART DISEASE; MIDDLE AGED; REFERENCE VALUE; REPRODUCIBILITY; SEXUAL CHARACTERISTICS; STATISTICS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; COHORT STUDIES; DIAGNOSTIC TEST APPROVAL; FEMALE; HEART DISEASES; HUMANS; LIMIT OF DETECTION; MALE; MIDDLE AGED; REAGENT KITS, DIAGNOSTIC; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SEX CHARACTERISTICS; STATISTICS AS TOPIC; TROPONIN I; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; YOUNG ADULT;

EID: 85047083165     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2018.06.008     Document Type: Erratum

References (41)

1. Alpert, J.S., Thygesen, K., Antman, E., Bassand, J.P., Myocardial infarction redefined - a consensus document of the joint uropean ociety of ardiology/merican ollege of ardiology ommittee for the redefinition of myocardial infarction. J. Am. Coll. Cardiol. 36 (2000), 959–969.
2. Thygesen, K., Alpert, J.S., White, H.D., Joint esc/accf/aha/whf task force for the redefinition of myocardial infarction. Universal definition of myocardial infarction. J. Am. Coll. Cardiol. 50 (2007), 2173–2195.
3. Thygesen, K., Alpert, J.S., Jaffe, A.S., Simoons, M.L., Chaitman, B.R., White, H.D., Third universal definition of myocardial infarction. J. Am. Coll. Cardiol. 60 (2012), 1581–1598.
4. Morrow, D.A., Cannon, C.P., Jesse, R.L., Newby, L.K., Ravkilde, J., Storrow, A.B. et al., National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: clinical characteristics and utilization of biochemical markers in acute coronary sndromes. Circulation 115 (2007), e356–e375.
5. Roffi, M., Patrono, C., Collet, J.P., Mueller, C., Valgimigli, M., Andreotti, F. et al., 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J. 37 (2016), 267–315.
6. Amsterdam, E.A., Wenger, N.K., Brindis, R.G., Casey, D.E. Jr., Ganiats, T.G., Holmes, D.R. Jr. et al., 2014 AHA/ACC guideline for the management of patients with non-st-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation 130 (2014), 2354–2394.
7. Apple, F.S., Jaffe, A.S., Collinson, P., Mockel, M., Ordonez-Llanos, J., Lindahl, B. et al., IFCC educational materials on selected analytical and clinical applications of high sensitivity cardiac troponin assays. Clin. Biochem. 48 (2015), 201–203.
8. Apple, F.S., Sandoval, Y., Jaffe, A.S., Ordonez-Llanos, J., Cardiac troponin assays: guide to understanding analytical characteristics and their impact. Clin. Chem. 63 (2017), 73–81.
9. Wu, A.H.B., Christenson, R.H., Greene, D.N., Jaffe, A.S., Kavsak, P.A., Ordonez-Llanos, J., Apple, F.S., Clinical laboratory practice recommendations for the use of cardiac troponin in acute coronary syndrome: expert opinion from the academy of the American Association for Clinical Chemistry and the task force on clinical applications of cardiac bio-markers of the International Federation of Clinical Chemistry and Laboratory Medicine. Clin. Chem. 64 (2018), 645–655.
10. Mills, N.L., Lee, K.K., McAllister, D.A., Churchhouse, A.M., MacLeod, M., Stoddart, M. et al., Implications of lowering threshold of plasma troponin concentration in diagnosis of myocardial infarction: cohort study. BMJ, 344, 2012, e1533.
11. 1, Churchhouse, A.M., Lee, K.K., Anand, A., Gamble, D., Shah, A.S. et al., Implementation of a sensitive troponin I assay and risk of recurrent myocardial infarction and death in patients with suspected acute coronary syndrome. JAMA 305 (2011), 1210–1216.
12. Hachey, B.J., Kontos, M.C., Newby, L.K., Christenson, R.H., Peacock, W.F., Brewer, K.C., McCord, J., Trends in use of biomarker protocols for the evaluation of possible myocardial infarction. J. Am. Heart Assoc., 6(9), 2017 pii: e005852.
13. Collinson, P., Hammerer-Lercher, A., Suvisaari, J., Apple, F.S., Christenson, R.H., Pulkki, K. et al., How well do laboratories adhere to recommended clinical guidelines for the management of myocardial infarction: the cardiac marker guidelines uptake in Europe Study (Carmague). Clin. Chem. 62 (2016), 1264–1271.
14. Wildi, K., Gimenez, M.R., Twerenbold, R., Reichlin, T., Jaeger, C., Heinzelmann, A. et al., Misdiagnosis of myocardial infarction related to limitations of the current regulatory approach to define clinical decision values for cardiac troponin. Circulation 131 (2015), 2032–2040.
15. PATHFAST cTnI-II REF PF1101-K, FDA cleared May 2011. 510(k) substantial equivalence determination decision summary assay only template. https://www.accessdata.fda.gov/cdrh_docs/reviews/K100130.pdf (accessed 31-Dec-2017).
16. Armbruster, D.A., Pry, T., Limit of Blank, Limit of Detection and Limit of Quantitation. Clin Biochem Rev 29:Suppl. 1 (2008), S49–S52.
17. Wu, A.H.B., Apple, F., Love, S.A., Koch, D., Myers, G.L., Christenson, R.H., Creation of a universal sample bank for determining the 99th percentile for cardiac troponin assays. J Appl Lab Med 1 (2017), 711–719.
18. Levey, A.S., Stevens, L.A., Schmid, C.H., Zhang, Y.L., Castro, A.F. III, Feldman, H.I. et al., A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 15 (2009), 604–612.
19. Ozarda, Y., Reference intervals: current status, recent developments and future considerations. Biochem Med (Zagreb) 15:26 (2016), 5–11.
20. Harrell, F.E., Davis, C.E., A new distribution-free quantile estimator. Biometrika 69 (1982), 635–640.
21. 510 (k) substantial equivalence determination decision summary for Dimension Vista® N-terminal Pro-Brain Natriuretic Peptide (PBNP) Flex® Reagent Cartridge (K6423A). https://www.accessdata.fda.gov/cdrh_docs/reviews/K080578.pdf (accessed 16-DEC-2017).
22. Fradley, M.G., Larson, M.G., Cheng, S., McCabe, E., Coglianese, E., Shah, R.V. et al., Reference limits for n-terminal protype natriuretic peptide in healthy individuals (from the Framingham Heart Study). Am. J. Cardiol. 108 (2011), 1341–1345.
23. Cullen, L.A., Mills, N.L., The use of sex-specific cutpoints for high-sensitivity cardiac troponin assays. Clin. Chem. 63 (2017), 261–263.
24. Trambas, C., Pickering, J.W., Than, M., Bain, C., Nie, L., Paul, E. et al., Impact of high-sensitivity troponin I testing with sex-specific cutoffs on the diagnosis of acute myocardial infarction. Clin. Chem. 62 (2016), 831–838.
25. Shah, A.S., Griffiths, M., Lee, K.K., McAllister, D.A., Hunter, A.L., Ferry, A.V. et al., High sensitivity cardiac troponin and the under-diagnosis of myocardial infarction in women: prospective cohort study. BMJ, g7873, 2015, 350.
26. Giannitsis, E., Potential concerns regarding the use of sex-specific cutpoints for high-sensitivity troponin assays. Clin. Chem. 63 (2017), 264–266.
27. Rubini Giménez, M., Twerenbold, R., Boeddinghaus, J., Nestelberger, T., Puelacher, C., Hillinger, P. et al., Clinical effect of sex-specific cutoff values of high-sensitivity cardiac troponin t in suspected myocardial infarction. JAMA Cardiol(8), 2016, 912–920.
28. Gunsolus, I.L., Jaffe, A.S., Sexter, A., Schulz, K., Ler, R., Lindgren, B. et al., Sex-specific 99th percentiles derived from the AACC Universal Sample Bank for the Roche Gen 5 cTnT assay: comorbidities and statistical methods influence derivation of reference limits. Clin. Biochem. 50 (2017), 1073–1077.
29. Package Insert for 5th Generation, FDA cleared “Instructions for use”. https://usdiagnostics.roche.com/en/documentation.html#/c/PI/q/troponin%2Bt/s/SCORE_DESC (accessed 19-Dec-17).
30. Peacock, W.F., Diercks, D., Birkhahn, R., Singer, A.J., Hollander, J.E., Nowak, R. et al., Can a point-of-care troponin I assay be as good as a central laboratory assay? A Midas investigation. Ann Lab Med 36 (2016), 405–412.
31. Parikh, R.H., Seliger, S.L., de Lemos, J., Nambi, V., Christenson, R., Ayers, C. et al., Prognostic significance of high-sensitivity cardiac troponin T concentrations between the limit of blank and limit of detection in community-dwelling adults: a metaanalysis. Clin. Chem. 61 (2015), 1524–1531.
32. Boeddinghaus, J., Nestelberger, T., Twerenbold, R., Wildi, K., Badertscher, P., Cupa, J. et al., Direct comparison of 4 very early rule-out strategies for acute myocardial infarction using high-sensitivity cardiac troponin I. Circulation 135 (2017), 1597–1611.
33. Pickering, J.W., Than, M.P., Cullen, L., Aldous, S., Ter Avest, E., Body, R. et al., Rapid rule-out of acute myocardial infarction with a single high-sensitivity cardiac troponin t measurement below the limit of detection: a collaborative meta-analysis. Ann Intern Med 166 (2017), 715–724.
34. Body, R., Carley, S., McDowell, G., Jaffe, A.S., France, M., Cruickshank, K. et al., Rapid exclusion of acute myocardial infarction in patients with undetectable troponin using a high sensitivity assay. J. Am. Coll. Cardiol. 58 (2011), 1332–1339.
35. Bandstein, N., Ljung, R., Johansson, M., Holzmann, M.J., Undetectable high sensitivity troponin T level in the emergency department and risk of myocardial infarction. J. Am. Coll. Cardiol. 63 (2014), 2569–2578.
36. Body, R., Burrows, G., Carley, S., Cullen, L., Than, M., Jaffe, A.S. et al., High-sensitivity cardiac troponin T concentrations below the limit of detection to exclude acute myocardial infarction: a prospective evaluation. Clin. Chem. 61 (2015), 983–989.
37. Sandoval, Y., Smith, S.W., Shah, A.S. et al., Rapid rule-out of acute myocardial injury using a single high-sensitivity cardiac troponin I measurement. Clin. Chem. 63 (2017), 369–376.
38. Seliger, S.L., Hong, S.N., Christenson, R.H. et al., High-sensitive cardiac troponin T as an early biochemical signature for clinical and subclinical heart failure: MESA (multi-ethnic study of atherosclerosis). Circulation 135 (2017), 1494–1505.
39. deFilippi, C.R., de Lemos, J.A., Christenson, R.H., Gottdiener, J.S., Kop, W.J., Zhan, M., Seliger, S.L., Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA 304 (2010), 2494–2502.
40. de Lemos, J.A., Drazner, M.H., Omland, T., Ayers, C.R., Khera, A., Rohatgi, A. et al., Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 304 (2010), 2503–2512.
41. Saunders, J.T., Nambi, V., de Lemos, J.A., Chambless, L.E., Virani, S.S., Boerwinkle, E. et al., Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the atherosclerosis risk in communities study. Circulation 123 (2011), 1367–1376.